Asset Details
Do you wish to reserve the book?
AI-augmented intraoperative decision-making workflows in diffuse midline glioma biopsy using cryosection pathology
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
AI-augmented intraoperative decision-making workflows in diffuse midline glioma biopsy using cryosection pathology
Do you wish to request the book?
AI-augmented intraoperative decision-making workflows in diffuse midline glioma biopsy using cryosection pathology
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
AI-augmented intraoperative decision-making workflows in diffuse midline glioma biopsy using cryosection pathology
2025
Overview
Cryosection pathology is essential for intraoperative diagnosis of diffuse midline gliomas, yet it often leads to diagnostic errors and may prompt unnecessary re-biopsies before completion of the formal molecular assessment. In this study, we propose an AI-augmented framework, CryoAID, for rapid molecular outcome prediction during surgery for patients with diffuse midline glioma. CryoAID integrates a generative model to correct cryosection artefacts and a pathology foundation model to predict molecular statuses directly from cryosection images. We validate CryoAID across multiple cohorts to predict tumoural molecular statuses in the internal (
n
= 326), external multi-centre (
n
= 52), and consecutive (
n
= 68) datasets. In particular, CryoAID accurately predicts major molecular statuses (e.g., ATRX, H3K27M, and TP53) using cryosection images that were previously deemed disqualified for molecular examinations. Beyond tumour cells, CryoAID reveals highly differential clinical features, including glial cell proliferation, abundant cytoplasm, and localised endothelial proliferation. In the retrospective analyses, CryoAID reduces re-biopsy rates by 26.4% and 26.6% in the internal and consecutive datasets, respectively. Our findings demonstrate that the AI-augmented pathology workflow can extract diagnostic value from specimens previously considered non-viable by traditional histopathology. This approach represents a shift towards real-time molecular pathology, potentially reducing re-biopsies and improving diagnostic precision for patients with diffuse midline glioma.
Cryosection pathology is essential for intraoperative diagnosis of diffuse midline gliomas (DMGs), but often requires re-sampling for an accurate assessment. Here, the authors develop CryoAID, an AI-augmented framework for rapid and accurate molecular outcome prediction during surgery for DMG, reducing re-biopsy rates in clinical cohorts.
